VOYAGER THERAPEUTICS
LIVE

Serial Number

98140452

Owner

Voyager Therapeutics, Inc.

Attorney

Keith Toms, Esq.

Filing Date

Aug 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

VOYAGER THERAPEUTICS Trademark

Serial Number: 98140452

VOYAGER THERAPEUTICS is a trademark filed by Voyager Therapeutics, Inc. on August 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Voyager Therapeutics, Inc. (18 trademarks)

75 Hayden Avenue
Lexington, MA 02421

Entity Type: 03

Trademark Details

Filing Date

August 18, 2023

Registration Date

Not Registered

Published for Opposition

June 17, 2025

Goods & Services

Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; antibody and gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via antibody, gene replacement, gene knockdown, or vectorized antibodies; antibody and gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids viral platforms, and non-viral platforms, that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; pharmaceutical for the treatment of neurodegenerative diseases and diseases of the central nervous system, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, Huntington's disease, and prion disease

Medical services provided for clinical trials; providing patient care for clinical trials; providing medical information in the field of gene therapy; providing a website featuring medical information; medical treatment of neurological diseases, neurodegenerative diseases, and diseases of the central nervous system, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, and Huntington's disease, and prion disease

Collaboration services in the field of platform technologies for delivery of therapies and pharmaceuticals, namely, licensing of intellectual property

Biotechnology research services; research and development of platform technologies for delivery of therapies; research and development of platform technologies for delivery of gene therapies, antibody therapies and pharmaceuticals; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic delivery of therapies and pharmaceuticals; Pharmaceutical research and development in the field of gene therapy and antibody therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy and antibody therapy; pharmaceutical research services; research and development of pharmaceutical preparations for non-viral and gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development in the pharmaceutical and biotechnology fields; research and development regarding the delivery of therapies across the blood-brain barrier; research and development regarding the non-viral and viral vectors for the delivery of therapeutic agents; research and development regarding the identification and targeting of specific cells and tissues for gene therapy; providing scientific research information in the field of clinical trials; hosting a website featuring medical research information

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2026 EXRA
SOU EXTENSION 2 GRANTED
Aug 12, 2026 EX2G
SOU EXTENSION 2 FILED
Aug 12, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 14, 2026 EXRA
SOU EXTENSION 1 GRANTED
Feb 4, 2026 EX1G
SOU EXTENSION 1 FILED
Feb 4, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 4, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 12, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 13, 2025 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 17, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 23, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 23, 2024 GNSL
SUSPENSION LETTER WRITTEN
Sep 23, 2024 CNSL
EXAMINER'S AMENDMENT ENTERED
Sep 20, 2024 XAEC
ASSIGNED TO LIE
Sep 20, 2024 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 19, 2024 CNEA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 23, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 23, 2024 XELR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 22, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 22, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 22, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 23, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 17, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 19, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 18, 2023 NWOS
NEW APPLICATION ENTERED
Aug 22, 2023 NWAP